H1的动态

#mRNA_Vaccine_And_Therapeutics Market Projected to Grow with magnificent CAGR During the 2022-2030 >>https://lnkd.in/gPw6zWyg mRNA #vaccine is the #drugs prepared using advanced #technologies using #mRNA as the #genetic #material. mRNA vaccines are a more efficient alternative owing to their #enhanced immunogenicity, higher #potency, rapid #development, relatively cheaper and #safer over #conventional #vaccines. Pfizer, Moderna., BioNTech SE, GSK, Daiichi Sankyo, Inc. #vaccine #technologies #health #genetic #vaccinedevelopment #vaccines

The manufacturing of #COVID-19 vaccines demonstrated how #vaccineproduction can be rapidly scaled up with faster regulatory approval and time to market. Advances in purification technology and analytical tools in recent years has led to an increased market value and manufacturing capacity for vaccines; however, challenges remain. This infographic offers a step-by-step overview of manufacturing and analytical methods for four key #vaccine types: #VLP (virus-like-particle), subunit, #mRNA, and #viralvectorvaccines View below:

Big News for Novavax ?? Sanofi has inked a deal with Novavax worth up to $1.4 billion for its COVID-19 vaccine, signaling a substantial uplift for the Maryland-based biotech firm. This marks a significant turnaround, as Novavax’s market cap stands at just $627 million. What’s the deal? Sanofi is setting down $500 million upfront, targeting not only the co-commercialization of the existing vaccine but also the development of a novel flu-COVID combo vaccine. With potential milestones adding up to $700 million and another $200 million tied to additional vaccines, this deal could be a game-changer for Novavax. Stock Surge: Following the announcement, Novavax's stock soared, nearly doubling in early trading—a welcome change from the recent struggles after a 25% drop post-Q4 earnings report. From Sanofi’s Perspective: Jean-Francois Toussaint, the Head of Vaccines R&D at Sanofi, highlighted the strategic move to tackle flu and COVID with a single shot, enhancing patient convenience and protection. A Strategic Shift: Back in 2021, Sanofi acquired mRNA developer Translate Bio for $3.2 billion, bolstering its arsenal in vaccine technology. Today, they’re further expanding their footprint with this strategic partnership, taking a near 5% stake in Novavax. ?? Stay tuned as these developments unfold, potentially setting a new course for vaccine technology and market dynamics. (What’s your take on this massive pharmaceutical move? Drop your thoughts below! ??)

In May, the online discussions among healthcare professionals (HCPs) regarding pharmaceutical companies primarily revolved around three key topics: 1. An app created by Abbott to assess the risk of death or hospitalisation in patients with heart failure. 2. AstraZeneca's decision to withdraw its COVID-19 vaccine. 3. A second fire occurring at the Novo Nordisk headquarters in Denmark. For detailed insights into the sentiments expressed concerning these events, please refer to the full tracker. https://lnkd.in/emHBAFjs #pharma #healthcare #COVID19

The manufacturing of #COVID-19 vaccines demonstrated how #vaccineproduction can be rapidly scaled up with faster regulatory approval and time to market. Advances in purification technology and #analyticaltools in recent years has led to an increased market value and manufacturing capacity for vaccines; however, challenges remain. This #infographic offers a step-by-step overview of manufacturing and analytical methods for four key #vaccine types: #VLP (virus-like-particle), subunit, #mRNA, and #viralvectorvaccines View below:

GeoVax $GOVX; Achieves Milestone in Transition to Commercially Validated Manufacturing System #finance #stocks #marketing #stockmarket #pharma #pharmaceutical #biotech #biotechnology https://hubs.ly/Q02nmWgY0

How High-Pressure Homogenization Contributes to Vaccine Production In the pharmaceutical industry, cutting-edge solutions are essential to ensure maximum efficiency and compliance with strict international regulations. This is particularly true in the production of vaccines, where precision and reliability are paramount.?? The GEA Pharma Skid high-pressure homogenizers are designed to achieve exceptional results in cell disruption and micronization—critical processes for creating emulsions and dispersions that meet the stringent requirements for intravenous administration, such as those needed for vaccines. Our advanced technologies are now being used to support innovative research in the development of vaccines against various severe diseases, including certain types of cancer and conditions like shingles. While we are still in the early stages, the goal is to develop "tailor-made" vaccines, customized to each patient's specific characteristics and the nature of the disease. This approach aims to increase effectiveness and provide meaningful solutions to countless people worldwide. ?? These advancements are made possible thanks to GEA’s technology and our unwavering commitment to research, continually delivering innovative and effective solutions for every challenge. #GEA #homogenizer #Pharma #Vaccine #R&D #Innovation #PharmaSkid https://go.gea/3op

Over the past two years, five pharmaceutical companies have committed to setting up plants here, which will churn out over a billion doses annually. The products range from traditional types such as live-attenuated and recombinant vaccines to the latest mRNA ones, with the first output set to be rolled out as early as 2023. BioNTech is among the companies setting up a vaccine plant to provide a “rapid response" on its vaccine production capability for Southeast Asia to address potential pandemic threats. With more global companies setting their expansion foresight in Singapore, not only shall this further strengthen our healthcare ecosystem and enhance the pandemic resilience of Singapore and the region by providing faster access to vaccines and therapeutics. We can foresee more employment and talent demand required in the pharma landscape. If you are keen to hop on to this industry, connect with our recruiters below.

KCAS Bio - Lyon is excited to participate in the 15th Open Scientific EIP Symposium on the Immunogenicity of Biopharmaceuticals. Christine BAIN and Alain POYAU will be delighted to engage in discussions regarding immnogenicity assays and their clinical implications. Additionally, our team will showcase a scientific poster titled "Monitoring immunogenicity of your candidate vaccine by ELISpot: How to reduce assay variability?" https://lnkd.in/gWQdzBjR #EIP #Immunogenicity #Vaccines #ELISpot

December 18, 2023, Bogotá, Colombia – SINOVAC BIOTECH LTD., a renowned global provider of bio-pharmaceutical products, announced today its partnership with the District of Bogotá in establishing BogotáBio, a company focused on vaccine and biologics development and production, marking a significant milestone in the country's pursuit of health sovereignty. The launch ceremony presided over by SINOVAC BIOTECH LTD.'s Chairman, President & CEO , Mr. Weidong Yin, and Bogotá's Mayor, Claudia López, marked the official start of this pioneering enterprise in Colombia. The company's incorporation was formalized, unveiling its corporate identity, symbolizing a steadfast commitment to public health and Colombia's technological and industrial advancement. Mr. Yin noted that the COVID-19 pandemic has made all countries fully realize the importance of vaccines for national security and people's health and Bogotá Government made the choice of SINOVAC as a strategic partner came after evaluating proposals from 15 biopharmaceutical companies around the world. Bogotá Government and SINOVAC have formulated a 10-year development plan and will establish a vaccine production base which can produce multiple types of vaccines through technical cooperation."We will carry out project construction and personnel training in accordance with the most advanced international standards, in order to achieve localized production of vaccines in Colombia as soon as possible. We firmly believe that this project will benefit the people of Colombia." https://lnkd.in/gTzVy2j5